113770-65-3

Basic information

• Product Name: cis-[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl-p-toluenesulfonate
• Synonyms: cis-[2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl-p-toluenesulfonate;cis-(±)-2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolane-4-methanol 4-methylbenzenesulfonate;cis-(∴)-2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolane-4-methanol 4-methylbenzenesulfonate;CIS-TRITOSYLATE;benzoxazolium, 3-octadecyl-2-[3-(3-octadecyl-2(3h)-benzoxazolylidene)-1-propeny;1-[4-[(2RS,4SR)-2-(2,4-dichlorophenyl)-2-[1H-1,2,4-triazol-1-yl)methyl]-1,3-di- oxolan-4-yl]methoxy] tosylate;((2S,4S)-2-((1H-1,2,4-Triazol-1-yl)Methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)Methyl 4-Methylbenzenesulfonate;((2S,4S)-2-((1H-1,2,4-Triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methyl 4-meth
• CAS NO: 113770-65-3
• Molecular Formula: C20H18Cl2N3O5S-
• Molecular Weight: 484.36
• Product Categories: Pharmaceutical Intermediates
• Mol File: 113770-65-3.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 657.7±65.0 °C(Predicted)
• Appearance: /
• Density: 1.49
• Refractive Index: 1.671
• Storage Temp.: 2-8°C
• PKA: 2.94±0.12(Predicted)
• CAS DataBase Reference: cis-[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl-p-toluenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: cis-[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl-p-toluenesulfonate(113770-65-3)
• EPA Substance Registry System: cis-[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl-p-toluenesulfonate(113770-65-3)

Safety Data

• Hazardous Substances Data: 113770-65-3(Hazardous Substances Data)

Usage

General Description

"Cis-[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl-p-toluenesulfonate" is a highly specific chemical compound that contains a variety of chemical structures, including a dichlorophenyl group, a triazol ring, a dioxolane ring, and a toluenesulfonate group. The name indicates the presence of isomerism (cis-), which is a type of structural variation in which atoms or groups of atoms can occupy different positions in relation to a given plane or other reference. The numberings in the name illustrate the specific arrangement of these functional groups attached to the parent structures. Given its specific structural design, this compound likely possesses unique physiological and chemical properties, however, specific information about the compound's uses, reactivity, and safety is not provided. As with other organic compounds, careful handling and appropriate safety measures should be taken when using this chemical compound in research or industrial applications.

InChI:InChI=1/C20H19Cl2N3O5S/c1-13-2-5-19(31(26,27)28)14(6-13)7-16-9-29-20(30-16,10-25-12-23-11-24-25)17-4-3-15(21)8-18(17)22/h2-6,8,11-12,16H,7,9-10H2,1H3,(H,26,27,28)/p-1

Upstream product

• 2631-72-3 2,4-dichlorophenacyl bromide 
• 23735-43-5 (S)-1-O-tosyl-2,3-O-isopropylideneglycerol 
• 98-59-9 p-toluenesulfonyl chloride 
• 50765-70-3 (S)-1-tosyloxy-2,3-propanediol 
• 58905-16-1 1-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethanone 
• 23788-74-1 (R)-2,2-dimethyl-1,3-dioxolane-4-ylmethyl p-toluenesulfonate 
• 41274-09-3 (R)-3-tosyloxy-1,2-propanediol 
• 4252-78-2 2,2',4'-trichloroacetophenone 
• 172587-60-9 (-)-(2S,cis)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolane-4-methanol 
• 67914-84-5 cis-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolane-4-methanol benzoate (ester) 
• 172587-56-3 Benzoic acid (2R,4R)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethyl ester 
• 172587-57-4 (2R,4S)-(+)-2-(2,4-dichlorophenyl)-2-<(1H-1,2,4-triazol-1-yl)methyl>-1,3-dioxolane-4-methanol 
• 23737-51-1 solketal tosylate 
• 51704-66-6 (+/-)-2,3-dihydroxypropyl tosylate 

Downstream Products

• 848585-69-3 (2R,4R,2'S)-Itraconazole 
• 154003-18-6 (2R,4S,2'R)-Itraconazole 
• 154003-20-0 (2S,4R,2'R)-Itraconazole 
• 848585-71-7 (2S,4S,2'S)-Itraconazole 
• 848585-68-2 (2R,4R,2'R)-Itraconazole 
• 154003-17-5 (2R,4S,2'S)-Itraconazole 
• 154003-19-7 (2S,4R,2'S)-Itraconazole 
• 848585-70-6 (2S,4S,2'R)-Itraconazole 
• 1339803-62-1 cis-(2S,4R)-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-methyl-3H-1,2,4-triazol-3-one 

Relevant articles and documents

-

-

An optical pure itraconazole key intermediate and synthetic method and by the intermediate synthesis of optically pure itraconazole method

The invention disclsoes an optically pure itraconazole key intermediate and synthetic method thereof, and a method for synthesizing the optically pure itraconazole from the intermediate. The method of the invention uses 1-(2,4-dichlorobenzene)-2-(1-methylene-1,2,4-triazole)-1-ketone for preparing the optically pure itraconazole key intermediate, and the optically pure itraconazole key intermediate is used for the preparation of optically pure itraconazole. The method uses easily available raw materials, not only reduces the production cost, but also obtains the product with high purity; through the control of the optical purity of the key intermediate compound VII, the optical purity of the target product itraconazole can be effectively controlled; therefore, the invention has with industrial value.

Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic

Itraconazole (ITZ) is an FDA-approved member of the triazole class of antifungal agents. Two recent drug repurposing screens identified ITZ as a promising anticancer chemotherapeutic that inhibits both the angiogenesis and hedgehog (Hh) signaling pathways. We have synthesized and evaluated first- and second-generation ITZ analogues for their anti-Hh and antiangiogenic activities to probe more fully the structural requirements for these anticancer properties. Our overall results suggest that the triazole functionality is required for ITZ-mediated inhibition of angiogenesis but that it is not essential for inhibition of Hh signaling. The synthesis and evaluation of stereochemically defined des-triazole ITZ analogues also provides key information as to the optimal configuration around the dioxolane ring of the ITZ scaffold. Finally, the results from our studies suggest that two distinct cellular mechanisms of action govern the anticancer properties of the ITZ scaffold.